Chronic Hepatitis B: Update of Recommendations

Hepatology

Volumn 39, Issue 3, 2004, Pages 857-861

  Lok, Anna S F ^a,c   McMahon, Brian J ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; HEPATITIS B(E) ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; PLACEBO;

CANCER CHEMOTHERAPY; CHILD; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INDICATION; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; NEPHROTOXICITY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; RISK BENEFIT ANALYSIS; SEROCONVERSION; SIDE EFFECT; SURVIVAL RATE; VIRUS REPLICATION;

HEPATITIS B, CHRONIC; HUMANS;

EID: 1542515092     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20110     Document Type: Review

References (19)

1. Lok ASF, McMahon BJ. AASLD Practice Guidelines: chronic hepatitis B. HEPATOLOGY 2001;1225-1241.
2. Jonas MM, Kelley DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, et al., for the International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N Eng J Med 2002;346:1706-1713.
3. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. HEPATOLOGY 2003;37:748-755.
4. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced H BeAg seroconversion. J Viral Hepat 2002;9:208-212.
5. van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, Heathcote J, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-424.
6. Guan R, Lai CL, Liaw YF, Lim SG, Lee CM. Efficacy and safety of 5-years lamivudine treatment of Chinese patients with chronic hepatitis B [abstract]. J Gastroenterol Hepatol 2001;16(suppl 1):A60.
7. Dienstag JL, Goldin RD, Heathcote EJ, Hann HWL, Woessner M, Stephenson SL, Gardner S, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003:124:105-117.
8. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. To continue or not to continue lamivudine therapy after emergence of YMDD mutations [abstract]. Gastroenterology 2002;122:A628
9. Wong VW, Chan HL, Wong ML, Leung N. Is it safe to stop lamivudine after the emergence of YMDD mutants during lamivudine therapy for chronic hepatitis B [abstract]?. J Hepatol 2002;36(suppl 1):177.
10. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jefferes L, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816.
11. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.
12. Hadziyannis S, Tassopoulos N, Heathcote J, Chang TT, Kitis G, Rizzetto M, Marcellin P, et al. Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B [abstract]. J Hepatol 2003;38(suppl 2): 143.
13. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann HL, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. HEPATOLOGY 2003;38:1419-1427.
14. Peters MG, Hann HW, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101.
15. Chang TT, Lim SG, Hadziyannis S, Tassopoulos N, Tong M, Sievert W, Fallis R, et al. Long-term safety of adefovir dipivoxil (ADV) 10 mg once daily for chronic hepatitis B (CHB): an integrated analysis of two phase III studies [abstract]. J Hepatol 2003;38(suppl 2):133.
16. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-297.
17. Lau GKK, He ML, Fong DYT, Bartholomeusz A, Au WY, Lie AKW, Locarini S, Liang R. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. HEPATOLOGY 2002;36:702-709.
18. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;115:58-62.
19. Chan TM, Fang GX, Tang CSO, Cheng IKP, Lai KN, Ho SKN. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. HEPATOLOGY 2002;36:1246-1252.